The impact of the COVID‐19 pandemic on source plasma donations

Abstract

AbstractWhile the COVID‐19 pandemic has impacted many aspects of healthcare, including routine blood donations, the impact of COVID‐19 on the donation of source plasma critical to many aspects of patient care, including apheresis procedures, has been more difficult to define. As production of plasma‐derived medicinal products (PDMPs) can take up to a year, shortages in source plasma donations may not be immediately appreciated. Given current shortages in PDMPs, in particular albumin, we examined the impact of COVID‐19 on source plasma donations. Our data demonstrate that source plasma donations were disproportionately impacted by COVID‐19 and that these shortages remained until the latter half of 2022. Given the time delay in PDMP manufacturing, these results suggest that while source plasma donation levels are returning to pre‐pandemic levels, shortages in PDMPs may not be quickly overcome. These results also highlight the unique vulnerabilities in plasma sourcing that may continue to manifest as PDMP shortages for years to come.